# Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/OCS/oculis-to-present-at-upcoming-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting
Ticker: OCS
Company: Oculis
Source: Oculis
Published: 2026-05-01 08:00 EST
Original Source URL: https://investors.oculis.com
## Summary

Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New post-hoc analysis of OCT scans on GCIPL and analysis of responders with

## Article Body
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New post-hoc analysis of OCT scans on GCIPL and analysis of responders with
## Recent Company News
- 2026-05-29 19:06 EST — [Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema](https://biopharmsignal.com/news/OCS/oculis-announces-topline-results-from-diamond-phase-3-trials-with-ocs-01-in-diabetic-macular-edema) — Source: Oculis
- 2026-05-14 20:05 EST — [Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors](https://biopharmsignal.com/news/OCS/oculis-publishes-results-of-2026-annual-general-meeting-and-announces-election-of-gregory-d-perry-to-its-board-of-directors) — Source: Oculis
- 2026-05-11 20:07 EST — [Oculis Reports Q1 2026 Financial Results and Provides Company Update](https://biopharmsignal.com/news/OCS/oculis-reports-q1-2026-financial-results-and-provides-company-update) — Source: Oculis
- 2026-05-07 08:58 EST — [Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial](https://biopharmsignal.com/news/OCS/oculis-announces-agreement-with-fda-on-a-special-protocol-assessment-spa-for-optic-neuritis-registrational-trial) — Source: Oculis
- 2026-05-05 08:00 EST — [Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting](https://biopharmsignal.com/news/OCS/latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting) — Source: Oculis
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)